SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Monogram Biosciences, Inc. (Nasdaq:MGRM) today announced results from three separate studies at the American Society for Clinical Oncology (ASCO) meeting in Orlando on the use of HERmark® and the VeraTag™ technology to identify distinct sub-populations of patient with HER-positive disease. Monogram’s unique measures of HER family protein levels resulted in improved correlations with the response to trastuzumab and with the histopathologic characteristics of breast cancer, as compared to conventional tests.